What You Should Know: - Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone. - This multi-omics approach is being used by Actuate Therapeutics in support
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Unintended Bias in AI-Driven Healthcare Applications
What You Should Know: - Over the past few years, Artificial Intelligence (AI), and more specifically, Machine Learning (ML) technology, have experienced rapid adoption in the healthcare space as tools for diagnosis and decision-making. Such tools are intended to address challenges in the healthcare system to both processes and put into practice the proliferating medical findings, and also to support delivery of the promise of personalized and precision medicine. - Unintended bias in AI and
Read More
5 Things Every Smart Operating Room Should Prioritize – Surgery
The healthcare industry is in the middle of deep digital transformation across every aspect of the patient journey. Technology has always been important in healthcare, but COVID-19 has accelerated advancements, improving the way care is delivered. The pandemic also increased patient interest in being more involved in their healthcare decisions. And when patients are more involved, they are typically more satisfied with their experience and have better health outcomes. From remote patient
Read More
Boosting Clinical Trial Recruitment Requires Humanity – and Technology
Clinical trials should be a time of promise for better patient outcomes, as they explore new ways to potentially help patients suffering from a variety of conditions. Instead, this phase of treatment development is often met with exasperation as patients, researchers, and drug developers deal with the many barriers to clinical trial recruitment and access. There are two central – and intrinsically linked – problems with the current state of clinical trial recruitment in the U.S.:
Read More
7 Life Sciences Executive Predictions to Watch in 2023
Tracy Curley, CFO and interim CEO at iSpecimen Focusing on the macroeconomic environment, which remains impacted by the lingering COVID-19 pandemic, there continues to be uncertainty about the strength of the global, Asia Pacific, UK and US economies. High-interest rates and a potential recession remain a concern for all market participants. At ISPC, we are closely monitoring the pace of specimen transactions. We believe that this industry can be resilient through a continued economic
Read More
Startup Velsera Launches to Advance Precision Health Through Data-Driven Solutions
What You Should Know: - New company Velsera was announced at the J.P. Morgan Healthcare Conference supported by thematic-focused impact fund Summa Equity (“Summa”). - Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world. Velsera creates a software platform out of science, technology, and informatics, making data actionable, accelerating the pace and potential of multi-omics. - Velsera, headquartered in
Read More
AWS Launches Amazon Omics for Precision Medicine
What You Should Know: - AWS announced the launch of a new service, Amazon Omics, to help bioinformaticians, researchers, and scientists store, query, and analyze genomic, transcriptomic, and other omics data and generate insights to improve health and advance scientific discoveries. - The explosion of “omics” data, such as genomic, transcriptomic, and proteomic data, is driving a new understanding of biology at the molecular level. This, in combination with
Read More
Tempus Launches Real-World Data-Driven Program to Accelerate Precision Oncology Research
What You Should Know: - Precision Medicine company Tempus announced the launch of Tempus+, a program connecting medical centers across the U.S. like Stanford Cancer Center, Baylor College of Medicine, Rush University Medical Center, and UCLA Jonsson Comprehensive Cancer Center, to advance cancer research and provide access to Tempus’ library of more than five million de-identified research records. - Tempus’ data library and data analytics platform, Lens, can now be used by researchers to
Read More
Assisted Polyp Detection Device Receives FDA Clearance
What You Should Know: - Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced recently that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. - The device was evaluated in the largest U.S.-based multicenter clinical study for a
Read More
Children’s Oncology Group Taps Tempus to Provide Genomic Sequencing for Pediatric Cancer Patients
What You Should Know: -Tempus, an $8B precision medicine company, is providing genomic sequencing for 300 eligible pediatric cancer patients annually through their new collaboration with the Children’s Oncology Group (COG). Tempus’ support for COG – a leader in pediatric oncology research – will assist with matching patients to clinical trials like the Pediatric MATCH Screening Trial APEC1621SC (NCT03155620), which is studying the effectiveness of genetic testing-directed treatment in
Read More
